Eiko LifeSciences creates 50:50 CBG venture with Rs 2.50 lakh
Key highlights
- Oval Eiko Resources was incorporated on November 12, 2026, with Rs 5 lakh paid-up capital.
- Eiko Scientific Solutions invested Rs 2.50 lakh for 50% ownership and 25,000 equity shares.
- Oval Eiko Resources reported nil turnover and had not commenced operations as of November 13, 2026.
- The venture's stated industry is CBG production and distribution, alongside other renewable-energy and industrial activities.
powered by IRIS
Eiko LifeSciences Limited entered renewable energy on November 12, 2026, by forming a 50:50 joint venture for compressed biogas, with its wholly owned subsidiary investing Rs 2.50 lakh in Oval Eiko Resources Private Limited's Rs 5 lakh paid-up capital. The new company had nil turnover and had not begun operations.
Know Eiko Lifesciences inside out
Results, valuation, peers and who's buying, in one view.
Why has Eiko LifeSciences formed a CBG joint venture?
Eiko LifeSciences said the venture is intended to diversify and expand its existing specialty chemicals and active pharmaceutical ingredients, or API, business into renewable energy, particularly compressed biogas, or CBG. The company disclosed the formation to BSE Limited on November 13, 2026, following an earlier announcement dated November 5, 2026.
The new company is Oval Eiko Resources Private Limited, incorporated on November 12, 2026. Eiko LifeSciences described the aim as exploring business opportunities in sustainable energy, industrial fuels, chemicals and other value-added products, while stating that the incorporation is intended to strengthen the group's long-term growth prospects.
The disclosed scope goes beyond CBG alone. Oval Eiko Resources is intended to undertake renewable-energy activities involving CBG, a condensation stabilization unit or industrial fuel and chemical unit, an essential oil unit and an engineered wood unit. The November 13, 2026 filing does not quantify planned production, investment beyond initial equity, revenue, plant location or a schedule for starting any of these activities.
CBG production and distribution is the named industry classification for the entity. The Ministry of Corporate Affairs certificate identifies Oval Eiko Resources as a company limited by shares, with Corporate Identity Number U35201MR2026PTC482646, registered at an address in Thane, Maharashtra. The certificate dated November 12, 2026 also says incorporation is not a licence or permission to conduct business where sectoral approvals are required.
Who owns Oval Eiko Resources and what did it cost?
Eiko LifeSciences' wholly owned subsidiary, Eiko Scientific Solutions LLP, owns 50% of Oval Eiko Resources, while Oval Projects Engineering Limited owns the other 50%. Eiko Scientific Solutions subscribed to 25,000 equity shares of Rs 10 each for cash consideration of Rs 2.50 lakh.
Oval Eiko Resources has authorised share capital of Rs 5 lakh and paid-up share capital of Rs 5 lakh. Since both figures were identical at incorporation on November 12, 2026, the disclosed initial capital was fully paid up; Eiko Scientific Solutions' Rs 2.50 lakh contribution represents half of that paid-up amount.
The transaction is a related-party transaction because Eiko Scientific Solutions is a wholly owned subsidiary of Eiko LifeSciences and holds 50% in the joint venture. Eiko LifeSciences stated that the transaction was conducted at arm's length. The filing records cash consideration, rather than a share swap or another form of payment.
Got a follow-up? Ask IRIS
Has Oval Eiko Resources started operations or generated revenue?
No, Oval Eiko Resources had not commenced business operations as of the November 13, 2026 disclosure, and its reported turnover was nil. This means the filing provides no operating revenue, historical profitability, customer base, production volume or installed capacity for the new renewable-energy business.
The entity was incorporated only on November 12, 2026, one day before Eiko LifeSciences' disclosure. There is therefore no three-year turnover history to compare with the existing specialty chemicals and API activities; the disclosed comparison is between an existing business base and a new entity with nil turnover that has yet to begin operations.
The filing uses the term acquisition in the prescribed disclosure format, but the mechanics described are the formation of a new private limited company through a joint venture. Eiko Scientific Solutions subscribed to newly issued equity at incorporation, rather than Eiko LifeSciences disclosing the purchase of an established operating CBG company.
What approvals and milestones has Eiko LifeSciences disclosed?
Eiko LifeSciences disclosed no government or regulatory approval requirement for the acquisition or incorporation in its Regulation 30 disclosure, marking the approval field as not applicable. It also marked the indicative period for completion as not applicable, consistent with its statement that the company had already been incorporated on November 12, 2026.
That disclosure does not establish that no future operating permits will be needed. The attached incorporation certificate specifically notes that it is not a licence or permission to conduct business or solicit public funds, and that permission from a sector regulator is necessary wherever required. The company did not identify a specific regulator, permit, plant approval or commercial-launch date.
The immediate completed milestone is legal incorporation and capital subscription: Eiko Scientific Solutions subscribed to 25,000 shares of Rs 10 each, representing its Rs 2.50 lakh contribution. The next commercial milestones, including project selection, construction, feedstock sourcing, CBG output, distribution arrangements, capital expenditure and sales, were not disclosed in the November 13, 2026 announcement.
For Eiko LifeSciences, the diversification has a defined 50:50 ownership structure and Rs 2.50 lakh of disclosed initial capital, but no operating metrics as of November 13, 2026. Management's stated plan is to explore sustainable-energy, industrial-fuel, chemical and value-added-product opportunities through the new vehicle, rather than a commitment to a particular facility or capacity target.
Conclusion
Eiko LifeSciences has formally added a renewable-energy route to its stated specialty chemicals and API base through a 50:50 partnership with Oval Projects Engineering. The financial commitment disclosed at incorporation is Rs 2.50 lakh, against Oval Eiko Resources' Rs 5 lakh paid-up capital, while the venture has no turnover because it has not yet commenced operations.
The next point to watch is whether Eiko LifeSciences discloses a specific CBG or allied-industrial project under its plan to explore sustainable energy and value-added products. Investors will also need future disclosures on required sector approvals, capital commitments, production capacity, commercial timing and revenue, none of which were provided in the November 13, 2026 filing.